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Oncogenic potential of truncated RXRα during
colitis-associated colorectal tumorigenesis by
promoting IL-6-STAT3 signaling
Xiaohong Ye1, Hua Wu1,2,3, Luoyan Sheng1, Yi-xin Liu1, Fang Ye1, Mo Wang1, Hu Zhou1, Ying Su3 &
Xiao-kun Zhang1,3
Retinoid X receptor-alpha (RXRα) is a potent regulator of inflammatory responses; however,
its therapeutic potential for inflammatory cancer remains to be explored. We previously
discovered that RXRα is abnormally cleaved in tumor cells and tissues, producing a truncated
RXRα (tRXRα). Here, we show that transgenic expression of tRXRα in mice accelerates the
development of colitis-associated colon cancer (CAC). The tumorigenic effect of tRXRα is
primarily dependent on its expression in myeloid cells, which results in interleukin-6 (IL-6)
induction and STAT3 activation. Mechanistic studies reveal an extensive interaction between
tRXRα and TRAF6 in the cytoplasm of macrophages, leading to TRAF6 ubiquitination and
subsequent activation of the NF-κB inflammatory pathway. K-80003, a tRXRα modulator
derived from nonsteroidal anti-inflammatory drug (NSAID) sulindac, suppresses the growth
of tRXRα-mediated colorectal tumor by inhibiting the NF-κB-IL-6-STAT3 signaling cascade.
These results provide new insight into tRXRα action and identify a promising tRXRα ligand for
treating CAC.
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Retinoid X receptor α (RXRα), a master member of thenuclear receptor superfamily, regulates a broad spectrum ofcellular processes under physiological and pathophysiolo-
gical conditions1–3. Targeted disruption of RXRα gene leads to
preneoplastic lesions in prostate4, alopecia, epidermal inter-
follicular hyperplasia, keratinocyte hyperproliferation, and aber-
rant terminal differentiation in the skin5 and the development of
cervical malignant lesions6. Altered expression and modification
of RXRα is also implicated in the development of a number of
malignancies1,3,7–9. RXRα binding to promyelocytic leukemia
(PML)/RARα is absolutely required for the development of acute
PML in transgenic mice, revealing its oncogenic potential when
acting inappropriately10,11. Interestingly, RXRα is proteolytically
cleaved in cancer cells12–26, implying that aberration in RXRα
signaling by limited proteolysis plays a role in cancer develop-
ment. Consistent with its role in cancer development, RXRα is
one of the most important targets for the development of phar-
macologic intervention and therapeutic applications1,7,27–30.
Notably, Targretin® was approved for treating human cutaneous
T cell lymphoma27. However, the therapeutic potential of RXRα
modulators remains to be explored, which requires our further
understanding of its role in tumorigenesis.
Chronic inflammation is an important contributor to increased
risk of cancer31,32. RXRα and ligands are potent regulators of
inflammatory responses. RXRα is highly expressed in all
inflammatory cell types33. Analysis of macrophage-specific RXRα
knockout mice revealed a critical role of RXRα in regulating
macrophage functions and inflammatory responses, including the
upregulation of chemokine expression and reduction of antiviral
responses in myeloid cells33–35. RXRα compounds also regulate
various inflammatory pathways in different cell types36–40.
Interestingly, certain anti-inflammatory agents, such as doc-
osahexaenoic acid41, R-etodolac42, and sulindac25, serve as RXRα
ligands, further supporting the role of RXRα in regulating
inflammatory responses. However, the underlying mechanisms
by which RXRα and ligands act, especially whether and how they
mediate and modulate the causal link between inflammation and
cancer remain obscure.
RXRα, like other nuclear receptors, consists of three distinct
domains: an N-terminal A/B region, a DNA-binding domain
(DBD), and a C-terminal ligand-binding domain (LBD)1,2,8.
The presence of well-conserved DBD in RXRα and other
nuclear receptors led to the discovery that members of the
nuclear receptor superfamily serve as ligand-dependent nuclear
transcription factors2. Subsequent studies, however, have
revealed that RXRα and other nuclear receptors could also act
independently of their DNA binding and transcription
function9,43. Orphan nuclear receptor Nur77 translocates from
the nucleus to the cytoplasm where it acts at mitochondria to
promote apoptosis44,45 and mitophagy46, whereas steroid hor-
mone receptors interact with the p85α subunit of phosphoi-
nositide 3-kinase (PI3K) in the cytoplasm to modulate the PI3K
survival pathway47,48. RXRα is predominantly nuclear but can
migrate to the cytoplasm in response to inflammation23,25,49,50.
We previously reported that RXRα is proteolytically cleaved in
cancer cells, resulting in production of a truncated RXRα
(tRXRα) that lacks a portion of its N-terminal A/B domain25.
Unlike full-length RXRα, tRXRα is predominantly cytoplasmic
in response to inflammatory cytokine tumor necrosis factor-α
(TNFα), interacting with the p85α to activate the PI3K/AKT
pathway25. Thus tRXRα plays a critical role in mediating
the survival effect of inflammatory signaling through its non-
transcriptional action. The role of tRXRα was further illustrated
by our finding that tRXRα activity was inhibited by sulindac,
a nonsteroidal anti-inflammatory drug (NSAID)51, and
analogs21,25,52.
Colorectal cancer is closely associated with chronic
inflammation53,54, and regular use of NSAIDs lowers the mor-
tality from colorectal cancer55. RXRα downregulation38 or mal-
function of RXRα due to phosphorylation56 is associated with the
development of colorectal cancer. To establish the tumorigenic
effect of tRXRα in the development of inflammation-associated
cancer and the therapeutic potential of targeting tRXRα-mediated
inflammatory signaling pathways, we have generated tRXRα
transgenic mice. Here we report our characterization of the
tRXRα transgenic mice with respect to its tumorigenic effects in
the development of colitis-associated colon cancer (CAC), the
underlying molecular mechanism, and the therapeutic
significance.
Results
Tumorigenic effect of tRXRα in mouse colon cancer model. To
test the tumorigenic effect of tRXRα in the development of
inflammation-associated cancer, we generated a loxP-tRXRα
(tRXRαflox) transgenic mouse line that contained loxP-flanked
SV40 poly A sequences between CAG promoter and tRXRα
cDNA sequences (Supplementary Fig. 1a). The loxP-tRXRα mice
were crossed with the CMV-Cre mice expressing Cre recombi-
nase under the control of cytomegalovirus (CMV) promoter to
produce transgenic tRXRα mice (Tg-tRXRα) (Supplementary
Fig. 1b) that express various levels of tRXRα in all the tissues
examined (Supplementary Fig. 1c). Tg-tRXRα mice, when com-
pared to control wild-type mice, showed certain aberrant crypts
in the colon of Tg-tRXRα mice (21-month old; Supplementary
Fig. 1d). To address the inflammatory effect of tRXRα, Tg-tRXRα
and control tRXRαflox mice were subjected to a single injection
with the colonotropic mutagen azoxymethane (AOM) followed
by three cycles of treatment with the luminal toxin dextran
sodium sulfate (DSS) (Fig. 1a), a standard CAC mouse model57.
We found that Tg-tRXRα mice lost less body weight than control
mice upon AOM/DSS treatment (Fig. 1b), suggesting that tRXRα
expression is involved in the proliferation and survival of colonic
epithelial cells. When tumor load was analyzed, Tg-tRXRα mice
showed increased tumor size (1.556 ± 0.07171 mm, N= 32) as
compared to control mice (1.281 ± 0.06477 mm, N= 16) (Fig. 1c).
The number of macroscopic tumors in Tg-tRXRα mice (3.2 ±
0.4667 tumors per mouse, N= 10) was also increased by two-fold
when compared to control animals (1.6 ± 0.3399 tumors per
mouse, N= 10) (Fig. 1d). As a result, Tg-tRXRα mice exhibited a
high frequency of larger tumors than control mice (Fig. 1e).
Histological analyses confirmed more aberrant crypt foci and
hyper-plastic crypts in Tg-tRXRα mice (Fig. 1f). These data sug-
gested that tRXRα may play a role in promoting the development
of CAC.
To further characterize the role of tRXRα, Tg-tRXRα mice
were treated with either DSS or AOM. When treated with three
cycles of DSS, we found that 2 of the 10 Tg-tRXRα mice
developed at least 1 tumor, while none of 12 control mice had
tumor under the same treatment (Fig. 1g; Table 1). Histological
examination confirmed the presence of adenomas in the colon
of Tg-tRXRα mice (Fig. 1g). AOM is a potent carcinogen that
causes a high incidence of colon cancer in rodents57,58.
Although none of the 6 control mice showed tumor 6 months
after repetitive intraperitoneal treatment of AOM, Tg-tRXRα
mice were much more sensitive to AOM treatment with 2 of the
6 Tg-tRXRα mice developing adenoma tumors (Fig. 1h; Table 1),
as revealed by histological examination (Fig. 1h), suggesting
that tRXRα is involved in modulating the initial response to
AOM. Taken together, these data demonstrate that tRXRα acts
at different levels to modulate the development of colorectal
tumor.
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Fig. 1 Tumorigenic effect of truncated retinoid X receptor α (tRXRα) in colitis-associated colon cancer mouse model. a Schematic representation of the
azoxymethane (AOM)/dextran sodium sulfate (DSS) procedure. i.p. intraperitoneal. b Body weight curve of control wild-type (WT) and Tg-tRXRα mice
during the course of AOM/DSS colitis. Data are mean ± SEM (standard error of the mean, n= 7), two-way analysis of variance (ANOVA). c Average
tumor size. Each dot represents a tumor. Data are mean ± SD (standard deviation, n= 10), t test. d Average tumor number. Each dot represents the tumor
number of one individual mouse. Data are mean ± SD (n= 10), t test. e Tumor size distribution. Data are mean ± SEM (n= 10), two-way ANOVA. f Colon
tumor sections from mice treated with AOM/DSS at 120 days were microscopically analyzed and examined for microscopic aberrant crypt foci (ACF) after
hematoxylin and eosin (H&E). Scale bars, 50 μm. Data are mean ± SEM (n= 10/8), t test. g Role of tRXRα in promoting DSS-induced colorectal
carcinogenesis. Schematic representation of the 2.5% DSS procedure (top panel). Colon sections from mice treated with DSS for 6 months were
microscopically analyzed and examined for microscopic ACF after H&E. Scale bars, 100 μm. Data are mean ± SEM (n= 10), t test. h Role of tRXRα in
promoting AOM-induced colorectal carcinogenesis. Schematic representation of the AOM (10mg/kg) procedure (top panel). Colon sections from mice
treated with AOM for 6 months were microscopically analyzed and examined for microscopic ACF after H&E. Scale bars, 100 μm. Data are mean ± SEM
(n= 6); ns not significant. *P < 0.05, **P < 0.01, ***P < 0.001
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Activation of STAT3 in colorectal tumors from Tg-tRXRα
mice. To explore the mechanism by which tRXRα impacts
tumorigenesis, we determined the activation of signaling path-
ways critical for colorectal carcinogenesis in tumor tissues from
Tg-tRXRα mice. In agreement with our previous finding that
tRXRα could activate the PI3K/AKT pathway25, the level of
pAKT was elevated in tumor tissues from Tg-tRXRα mice treated
with either AOM/DSS (Fig. 2a) or DSS alone (Fig. 2b). The A/B
domain of RXRα was shown to interact with β-catenin to trigger
its degradation59. Transgenic expression of tRXRα that lacks a
large portion of the A/B domain resulted in elevated level of β-
catenin independently of the treatment with AOM/DSS (Fig. 2a)
or DSS (Fig. 2b), likely due to the dominant-negative effect of
tRXRα. Interestingly, glycogen synthase kinase (GSK)-3β phos-
phorylation at Serine 9, which is a substrate of AKT60, was also
elevated in Tg-tRXRα mice. As phosphorylation of GSK-3β could
inhibit its activity known to induce β-catenin degradation60,
enhanced GSK-3β phosphorylation may also play a role in the
accumulation of β-catenin in Tg-tRXRα mice. Emerging evidence
has now revealed a critical role of signal transducer and activator
of transcription factor 3 (STAT3) activation in CAC
tumorigenesis61,62. We found that the level of phosphorylated
STAT3 was consistently elevated in Tg-tRXRα mice even in the
absence of treatment (Fig. 2a). In agreement with previous
reports62, AOM/DSS treatment resulted in STAT3 activation in
control mice. However, the activation was significantly enhanced
in Tg-tRXRα mice (Fig. 2a). Tg-tRXRα mice also exhibited higher
STAT3 activation upon DSS treatment compared to control mice
(Fig. 2b). Enhanced STAT3 activation by tRXRα was confirmed
by immunohistochemical staining in tumor tissues from Tg-
tRXRα and control mice treated with AOM/DSS or DSS (Fig. 2c).
These data revealed for the first time an important role of tRXRα
in the activation of STAT3 during colorectal tumorigenesis.
STAT3 could be activated in acute DSS-induced colitis,
protecting DSS-induced colonic epithelium injury61,62. We next
determined whether tRXRα expression impacted the activation of
STAT3 in the acute DSS-induced colitis model that uses a single
5-day course of DSS. Tg-tRXRα and control mice were treated
with 3% DSS in drinking water for 5 days followed by 4 days of
recovery in normal drinking water. Starting from day 1 of DSS
treatment, Tg-tRXRα mice lost significant more weight than
control animals but rapidly regained body weight after removal of
DSS from the drinking water (Fig. 2d). In contrast, control mice
continued to lose weight when DSS was removed from the
drinking water for 2 more days. As a result, colon length of Tg-
tRXRα mice was significantly longer compared to control mice
(Fig. 2e). Consistent with the initial rapid body weight loss, Tg-
tRXRα mice showed more epithelial injury and crypt incomplete
2 days after DSS treatment (Supplementary Fig. 2a). When
STAT3 activation was assessed, we found that DSS activation of
STAT3 occurred much earlier in Tg-tRXRα mice than in control
mice. Upregulation of STAT3 phosphorylation was seen 3 days
after DSS treatment in control mice. However, enhanced STAT3
activation was clearly seen 1 day after DSS treatment in Tg-tRXRα
mice and continued to increase after 3- or 5-day treatment
(Fig. 2f). The expression of the tissue-protective factors TFF3 and
Reglllγ, the downstream targets of STAT3, which are known to
mediate the protective effect of STAT3 on intestinal injury during
colitis62, was also significantly elevated in Tg-tRXRα mice
(Fig. 2g). Body weight recovery from DSS treatment is a result
of hyperproliferation of epithelial cells caused by STAT3
activation61. In line with their rapid recovery from body weight
loss, Tg-tRXRα mice exhibited less severe epithelial cell damage,
loss of crypts, and ulceration compared with control mice after
the acute DSS-induced colitis protocol (Supplementary Fig. 2b).
Immunohistochemical staining revealed enhanced Ki-67 and
proliferating cell nuclear antigen (PCNA) staining in the crypts of
Tg-tRXRα mice (Supplementary Fig. 2c, d). These results
suggested that STAT3 activation might play a role in tRXRα-
induced protection of intestinal cells from DSS-induced injury
and promotion of intestinal epithelial cell survival and
proliferation.
Increased infiltration of inflammatory cells in tRXRα tumor.
Our finding that STAT3 was strongly activated in Tg-tRXRα
tumors prompted us to study the mechanism by which tRXRα
promotes STAT3 activation. Cytokines especially interleukin
(IL)-6 and IL-11 through their respective receptors can phos-
phorylate and activate STAT361,62. Our immunohistochemical
study revealed much more pronounced staining of the macro-
phage marker CD68 in lamina propria of tumor tissue from Tg-
tRXRα mice than that from control mice treated with AOM/DSS
(Fig. 3a), indicating an increased infiltration of inflammatory cells
in Tg-tRXRα mice. In tumor developed from Tg-tRXRα mice
subjected to DSS treatment solely, a significant number of infil-
trated inflammatory cells was also detected (Fig. 3b). When the
expression levels of cytokines were examined in mice treated with
AOM/DSS, we found increased mRNA expression levels of IL-6,
IL-11, and TNFα in tumor tissues from Tg-tRXRα mice (Fig. 3c).
DSS-treated tRXRα mice also showed a noticeable increase in
mRNA expression of IL-6 and TNFα but not of IL-11 (Fig. 3d). In
contrast, Tg-tRXRα mice treated with AOM did not show any
apparent effect on macrophage infiltration (Supplementary
Fig. 3a) and the expression of IL-6, IL-11, and TNFα, although
cyclin D2 expression was increased (Supplementary Fig. 3b). IL-6
produced by lamina propria myeloid cells can protect intestinal
epithelial cells from apoptosis through activation of STAT362. We
found that Tg-tRXRα mice produced high level of serum IL-6
2 days after DSS treatment (Fig. 3e), in agreement with their rapid
recovery from body weight loss induced by DSS treatment
(Fig. 2d) and enhanced STAT3 activation (Fig. 2f). Together,
these results revealed an important role of tRXRα in modulating
inflammatory microenvironment and cytokine production, which
likely accounts for its activation of STAT3 during colitis.
Myeloid tRXRα expression is necessary for STAT3 activation.
Our observation that Tg-tRXRα mice could promote macro-
phage infiltration and cytokine production prompted us to
determine the effect of tRXRα expression in myeloid cells. Thus
we crossed tRXRαflox mice with LysM-Cre mice that express
Cre in myeloid cells63. For comparison, RXRαflox mice were
also crossed with LysM-Cre mice. These mice were initially
analyzed for tumorigenesis using the AOM/DSS protocol.
When LysM-tRXRα mice were analyzed, we found that the
average tumor size was much larger in this group of mice when
compared to LysM-cre mice (Fig. 4a). Overexpression of RXRα
in myeloid cells, however, did not apparently affect tumor load
Table 1 Transgenic expression of tRXRα promotes colorectal
carcinogenesis
Model DSS alone AOM alone
Group of mice WT tRXRα WT tRXRα
Number of mice 12 8 1 1 6 4 2
Tumors of mouse 0 0 2 1 0 0 1
Mice with tumours 0 20% 0 33.4%
P value 0.05211 0.0607
AOM azoxymethane, DSS dextran sodium sulfate, tRXRα trunacted retinoid X receptor
α, WT wild type
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Fig. 2 Activation of signal transducer and activator of transcription factor 3 in colorectal tumors from Tg-tRXRα mice. a, b Colon lysates from mice treated
with azoxymethane (AOM)/dextran sodium sulfate (DSS) for 120 days (a) or DSS for 6 months (b) were analyzed by immunoblotting. The bands are
quantified with Image J and normalized to β-actin. c Colon sections from mice treated with AOM/DSS for 120 days or DSS for 6 months were stained with
pSTAT3 antibody and analyzed the staining score. Scale bars, 25 μm. Data are mean ± SEM (n= 9), t test. d Body weight curve of control and Tg-tRXRα
mice during the course of acute DSS-induced colitis. Data are mean ± SEM (n= 8), two-way analysis of variance. e Colon length from mice after the course
of acute DSS-induced colitis. Data are mean ± SD (n= 8), t test. f Colonic lysates prepared from mice treated with DSS for the indicated time were
analyzed by immunoblotting. g RegIIIγ and Tff3 mRNA expression in mice treated with DSS for two days was analyzed by quantitative reverse
transcriptase–PCR. Data are mean ± SEM (n= 3), t test. *P < 0.05, **P < 0.01, ***P < 0.001. For immunoblotting, one of three or four similar experiments is
shown
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as LysM-RXRα mice showed similar tumor size and multi-
plicity with LysM-cre mice (Fig. 4a, b). Representative hema-
toxylin and eosin (H&E) images revealed an increase in tumor
size and high-grade dysplasia in LysM-tRXRα mice (Fig. 4c).
Thus tRXRα expression in myeloid cells could promote the
growth of AOM/DSS-induced colorectal tumor. The role of
tRXRα expression in myeloid cells was also illustrated by
increased macrophage infiltration (Fig. 4d) and mRNA
expression of IL-6, IL-11, and TNFα (Fig. 4e) in colon tumor
tissues from LysM-tRXRα but not in LysM-RXRα mice. When
the activation of STAT3 was examined, we found that it was
strongly activated in LysM-tRXRα but not in LysM-RXRα mice
(Fig. 4f), demonstrating that tRXRα expression in myeloid cells
is responsible for STAT3 activation. Thus tRXRα expression in
myeloid cells can induce IL-6 expression and STAT3 activation
in colorectal tumor.
Activation of the IKK-NF-κB pathway by tRXRα in macro-
phages. To determine the molecular mechanism by which tRXRα
expression in inflammatory cells promotes the growth of color-
ectal tumor through the IL-6-STAT3 pathway, we prepared bone
marrow-derived macrophages (BMDMs) from Tg-tRXRα mice
(tRXRα-BMDMs) and the corresponding control wild-type mice
(Supplementary Fig. 4a). tRXRα-BMDMs showed enhanced
mRNA expression of IL-6 and TNFα (Fig. 5a) and secretion of IL-
6 (Fig. 5b) in the absence or presence of lipopolysaccharide (LPS)
when compared to control BMDMs, consistent with data
obtained with LysM-tRXRα mice (Fig. 4e). As IL-6 is a nuclear
factor (NF)-κB-regulated cytokine in inflammatory cells61,62, we
determined whether tRXRα could promote the activation of
the IκB kinase (IKK)-NF-κB inflammatory pathway in macro-
phages. Treatment of control BMDMs with LPS resulted in IκBα
degradation, an indicative of IKK activation, in a time- and dose-
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dependent manner (Fig. 5c). When tRXRα-BMDMs were ana-
lyzed, we found that the basal level of IκBα was much lower in
tRXRα-BMDMs as compared to that in control BMDMs, sug-
gesting a role of tRXRα in activating IKK in an LPS-independent
manner. tRXRα could also potentiate the effect of LPS, as LPS-
induced IκBα degradation occurred much faster in tRXRα-
BMDMs than in control BMDMs. The role of tRXRα in activating
the IKK-mediated inflammatory pathway was also supported by
our data showing that stable expression of tRXRα in RAW264.7
cells (Supplementary Fig. 4b, c) enhanced the mRNA expression
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Fig. 4 Myeloid-specific truncated retinoid X receptor α expression is necessary for signal transducer and activator of transcription factor 3 activation and
colorectal carcinogenesis. a Tumor size from mice treated with azoxymethane (AOM)/dextran sodium sulfate (DSS) for 4 months. Each dot represents a
tumor. Data are mean ± SD (n= 6), one-way analysis of variance (ANOVA). b Tumor size distribution. Data are mean ± SEM (n= 6), two-way ANOVA.
c Colon tumor sections from mice treated with AOM/DSS for 4 months were stained with hematoxylin and eosin, Scale bars, 100 μm, and classified into
normal, low-grade, and high-grade lesions based on histological analysis (n= 6). Data are mean ± SEM (n= 6), two-way ANOVA. d Representative CD68
immunostaining image of colonic sections from mice treated with AOM/DSS (scale bars, 50 μm) and the score of the number of CD68-positve cells per
field. Each dot represents a mouse, and 10 fields were counted per mouse. Data are mean ± SD (n= 6), one-way ANOVA. e Relative mRNA expression
levels of the indicated genes in colon of mice treated with AOM/DSS were determined by quantitative reverse transcriptase–PCR. Data are mean ± SEM
(n≥ 4). one-way ANOVA. f Colon lysates from mice treated with AOM/DSS were analyzed by immunoblotting. The bands are quantified with Image J and
normalized to β-actin. One of three similar experiments is shown. *P < 0.05, **P < 0.01, ***P < 0.001
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Fig. 5 Truncated retinoid X receptor α (tRXRα) activation of the IKK-NF-κB pathway in macrophages. a Relative mRNA expression of interleukin (IL)-6 and
tumor necrosis factor-α (TNFα) in wild-type (WT) and tRXRα-BMDMs treated with or without lipopolysaccharide (LPS) for 3 h was determined by
quantitative reverse transcriptase–PCR (qRT-PCR), two-way analysis of variance (ANOVA). b WT and tRXRα-BMDMs cultured with Dulbecco’s modified
Eagle’s medium containing 10% fetal bovine serum for 3 days or treated with LPS (25 ng/ml) for 12 h were analyzed by enzyme-linked immunosorbent
assay (ELISA), t test. c Immunoblotting of lysates fromWT and tRXRα-BMDMs treated with or without LPS for the indicated time. d Expression of IL-6 and
TNFα mRNAs in RAW264.7 cells stably expressing green fluorescent protein (GFP), GFP-tRXRα, and GFP-RXRα was analyzed by RT-PCR. e Production of
IL-6 and TNFα in RAW264.7 cells stably expressing GFP, GFP-tRXRα, and GFP-RXRα was analyzed ELISA, one-way ANOVA. f Stable expression of tRXRα
in RAW264.7 cells potentiate LPS-induced IκBα degradation determined by immunoblotting. NS nonspecific. g Stable expression of tRXRα in RAW264.7
cells promotes LPS-induced NF-κB transactivation determined by reporter assay, two-way ANOVA. h Condition medium (CM) collected from WT- and
tRXRα-BMDMs cultured for 3 days and treated with or without LPS (25 ng/ml) for 12 h was used to culture mouse CT26 colon cancer cells for 1 h and
analyzed for signal transducer and activator of transcription factor 3 activation. Anti-IL-6 antibody (Ab) was incubated with CM of tRXRα-BMDMs for 1 h
before being used to culture CT26 cells. i CT26 cells were cultured with CM collected from WT- or tRXRα-BMDMs for 24 h in transwell and analyzed by
invasion assay. Representative images were photographed and migrated cells per field were counted. Scale bar, 200 μm, t test. j CM from tRXRα-BMDMs
was incubated with or without IL-6 antibody and used to culture CT26 cells for 36 h. Representative images were photographed and migrated cells per field
were counted. Scale bar, 200 μm, **P < 0.01 by t test. Data are mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. For immunoblotting, one of
three or four similar experiments is shown
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of IL-6 and TNFα (Fig. 5d) and their secretion in medium
(Fig. 5e), and the effect of LPS on inducing IκBα degradation
(Fig. 5f) and NF-κB transactivation (Fig. 5g). Conversely, trans-
fection of RXRα small interfering RNA (siRNA) in THP-1 cells,
which inhibited the expression of both RXRα and tRXRα, atte-
nuated the effect of LPS on inducing IκBα degradation (Supple-
mentary Fig. 4d) and activating the NF-κB reporter gene
transcription (Supplementary Fig. 4e). LPS-induced mRNA
expression of IL-6 and TNFα was also inhibited by RXRα siRNA
transfection (Supplementary Fig. 4f). Collectively, these results
demonstrated that tRXRα is involved in regulating the IKK-NF-
κB pathway in macrophages.
We next studied whether tRXRα activation of the IKK-NF-κB
inflammatory pathway in macrophages could serve to activate
STAT3 in colon cancer cells. Thus condition medium (CM) from
tRXRα-BMDMs were prepared and used to culture mouse CT26
colon cancer cells. Analysis of STAT3 activation in CT26 cells
revealed that CM from tRXRα-BMDMs was much more effective
than control BMDMs in activating STAT3 (Fig. 5h). Cell invasion
assays showed that the invasion of CT26 cells was significantly
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increased when they were cultured with CM from tRXRα-
BMDMs but not from control BMDMs (Fig. 5i). CM from
tRXRα-BMDMs could also potentiate the effect of LPS on
activating STAT3. Similar results were obtained when THP-1
cells were analyzed. In this case, transfection of tRXRα but not of
RXRα strongly induced the expression of IL-6 and TNFα
(Supplementary Fig. 5a). CM from tRXRα-transfected but not
from RXRα-transfected THP-1 cells enhanced STAT3 activation
in human HCT-116 colon cancer cells (Supplementary Fig. 5b).
In agreement with enhanced STAT3 activation, cell invasion
assays showed that the invasion of colon cancer cells was
significantly increased when they were cultured with CM from
tRXRα-BMDMs (Fig. 5i) or co-cultured with THP-1 cells
expressing tRXRα but not RXRα (Supplementary Fig. 5c).
Interestingly, tRXRα-expressing THP-1 cells could also promote
the expression of c-Myc and cyclin D1 and growth and invasion
of breast cancer cells (Supplementary Fig. 5d–f), indicating that
the effect of tRXRα in macrophages is not limited to colon cancer.
To determine whether IL-6 secreted from tRXRα-BMDMs played
a role in STAT3 activation, CM from tRXRα-BMDMs was
Fig. 6 Truncated retinoid X receptor α (tRXRα) interacts with TRAF6 and activates the IKK-NF-κB pathway. a Lysates from HEK293T cells transfected with
Flag-TRAF6 and/or increasing amounts of Myc-tRXRα were analyzed by immunoblotting. b CV-1 cells transfected with pNF-κB reporter alone or in
combination with RXRα or TRAF6 plasmids were analyzed for nuclear factor (NF)-κB transactivation by reporter assay. Data are mean ± SEM, *P < 0.05, by
two-way analysis of variance. c Subcellular localization of transfected Myc-tRXRα or Myc-RXRα in RAW264.7 cell was revealed by immunostaining using
anti-Myc antibody. The localization of endogenous p65 was stained by anti-p65 antibody. Green, Myc; red, p65; blue, DAPI. Scale bar, 10 μm. d Subcellular
localization of RXRα in macrophages of colon tumor tissues from mice treated with azoxymethane/dextran sodium sulfate for 120 days was determined by
immunostaining using ΔN197 anti-RXRα antibody. Green, CD68; Red, ΔN197; Blue, DAPI. Scale bar, 5 μm. e Wild-type (WT)- and tRXRα-BMDMs treated
with lipopolysaccharide (LPS; 50 ng/ml) for 15 min were analyzed for tRXRα interaction with TRAF6 by immunoprecipitation assays using anti-TRAF6
antibody. Immunoprecipitates were analyzed by immunoblotting. f, g HEK293T cells transfected with the indicated plasmids were analyzed by co-
immunoprecipitation assays using anti-Myc or anti-Flag antibody. h RAW264.7 transfected with HA-Ub, Flag-TRAF6, and Myc-tRXRα plasmids were
immunoprecipitated with anti-Flag antibody and analyzed for TRAF6 ubiquitination by immunoblotting. i WT- and tRXRα-BMDMs treated with or without
LPS (50 ng/ml) for 15 min were immunoprecipitated with anti-TRAF6 antibody and analyzed for TRAF6 ubiquitination by immunoblotting. For
immunoblotting, one of three or four similar experiments is shown
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ubiquitination by immunoblotting. h Schematic of tRXRα activation of the nuclear factor-κB pathway in macrophages and its role in promoting colon cancer
cell survival and proliferation through induction of signal transducer and activator of transcription factor 3 activation. *P < 0.05, **P < 0.01, ***P < 0.001. For
immunoblotting, one of three or four similar experiments is shown
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incubated with anti-IL-6 antibody. Neutralization of IL-6 activity
by anti-IL-6 antibody diminished its effect on inducing STAT3
activation in CT26 cells (Fig. 5h) and their invasion activity
(Fig. 5j), revealing a role of IL-6 in STAT3 activation and colon
cancer cell growth.
tRXRα interacts with TRAF6 in macrophages. TRAF6, an
essential upstream regulator of the IKK complex, is one of the key
signaling proteins in the IKK/NF-κB pathway in
macrophages64,65. TRAF6 is highly expressed in many different
types of cancer including colorectal cancer66,67. Interestingly, the
levels of TRAF6 were significantly elevated in Tg-tRXRα mice
challenged with either AOM/DSS (Fig. 2a) or DSS (Fig. 2b).
Colon tumor from LysM-tRXRα mice also showed a significant
elevated level of TRAF6 expression, which positively correlated
with STAT3 activation (Fig. 4f). These observations promoted us
to study whether and how TRAF6 mediated the effect of tRXRα
on activating the NF-κB-IL-6-STAT3 cascade. Indeed, cotrans-
fection of TRAF6 augmented the effect of tRXRα on inducing
IκBα degradation (Fig. 6a) and NF-κB transactivation (Fig. 6b),
suggesting a role of TRAF6 in mediating tRXRα activity.
TRAF6 activation of the IKK complex occurs in the
cytoplasm64,65. As the first step to study whether tRXRα
interacted with TRAF6, we examined the subcellular localization
of tRXRα in RAW246.7 cells and found that transfected Myc-
tRXRα resided in the cytoplasm while transfected Myc-RXRα was
in the nucleus (Fig. 6c). Immunostaining also revealed pre-
dominant cytoplasmic RXRα staining in colon tumor from Tg-
tRXRα mice (Fig. 6d). Thus tRXRα is a cytoplasmic protein in
macrophage. We then tested whether tRXRα could interact with
TRAF6 in the cytoplasm to modulate IKK activation. Immuno-
precipitation of TRAF6 from tRXRα-BMDMs resulted in co-
immunoprecipitation of tRXRα, which was slightly enhanced
when cells were treated with LPS (Fig. 6e). The interaction
appears to be very stable as trace amount of tRXRα expressed in
control BMDMs also interacted with TRAF6 in an LPS-
dependent manner. The LPS-dependent interaction between
endogenous TRAF6 and tRXRα was also observed in THP-1
and RAW264.7 cells (Supplementary Fig. 6a). The interaction
between TRAF6 and tRXRα was confirmed by data showing that
transfected Myc-tRXRα but not Myc-RXRα interacted with
transfected Flag-TRAF6 (Fig. 6f, g). Our mutagenesis analysis
revealed that the interaction involved the TRAF domain of
TRAF6 and the LBD of tRXRα (Supplementary Fig. 6b–d).
TRAF6 has E3 ligase activity, which can induce autoubiqui-
tination necessary for its activation of IKK64. We thus determined
whether tRXRα interaction with TRAF6 could result in TRAF6
autoubiquitination. Consistent with previous results68, trans-
fected Flag-TRAF6 was strongly ubiquitinated by LPS. Similar to
the effect of LPS, transfection of tRXRα promoted TRAF6
ubiquitination in a dose-dependent manner (Fig. 6h). In contrast,
transfection of RXRα had no such an effect (Supplementary
Fig. 6e). Stable expression of tRXRα in RAW264.7 cells
(Supplementary Fig. 6f) or tRXRα expression in BMDMs (Fig. 6i)
could potentiate the effect of LPS on inducing TRAF6
ubiquitination. Taken together, these results demonstrated that
tRXRα can activate the IKK-NF-κB pathway in macrophages by
inducing TRAF6 autoubiquitination through their direct
protein–protein interaction.
To study whether tRXRα production and interaction with
TRAF6 is clinic significant, we examined the expression of tRXRα
in tissue specimens from patients with ulcerative colitis and
colorectal cancer. Our results demonstrated that tRXRα was
expressed in colorectal tissues from three ulcerative colitis
patients while tRXRα was barely detected in colorectal tissues
from three healthy individuals (Fig. 7a). In addition, various
degrees of tRXRα expression were found in tumor tissues but not
the corresponding adjacent normal tissues from ten colon cancer
patients examined (Fig. 7b). Moreover, tRXRα expressed in
ulcerative colitis patients could interact with TRAF6. Thus tRXRα
production and interaction with TRAF6 appears to have role in
the pathogenesis of CAC.
Inhibition of the tumorigenic effect of tRXRα by K-80003. K-
80003 is a potent inhibitor of tRXRα through its unique tRXRα-
binding mechanism52. Administration of Tg-tRXRα mice with K-
80003 during the late stage of AOM/DSS-induced colorectal
carcinogenesis (Fig. 7c) significantly reduced colon tumor load,
reflected by both smaller tumor sizes and less tumor numbers as
compared to vehicle-treated mice (Fig. 7d, e; Supplementary
Fig. 7a, b). The potent anti-CAC effect of K-80003 was associated
with its inhibition of cell proliferation and induction of apoptosis
(Fig. 7f), suppression of the mRNA expression of IL-6, TNFα, and
IL-11 and the serum production of IL-6, and inhibition of STAT3
activation (Supplementary Fig. 7c–e). These data demonstrated
that K-80003 is a potent inhibitor of tRXRα-mediated IL-6-
STAT3 signaling during colorectal tumorigenesis. In vitro, K-
80003 inhibited LPS induction of mRNA expression of IL-6
(Supplementary Fig. 7f) in a dose-dependent manner in macro-
phages. It also suppressed the effect of LPS on inducing IκBα
degradation, NF-κB transactivation, and nuclear translocation
(Supplementary Fig. 7g–i) in RAW264.7 cells. Mechanistically, K-
80003 inhibited LPS-induced interaction of tRXRα with TRAF6
(Supplementary Fig. 7j) and TRAF6 ubiquitination (Fig. 7g).
Together, these results demonstrated that K-80003 is a potent
inhibitor of tRXRα-mediated CAC development by preventing
tRXRα interaction with TRAF6.
Discussion
Our characterization of the tRXRα transgenic mice revealed a
critical role of tRXRα in the development of CAC. Tg-tRXRαmice
displayed increased tumor frequency and enlarged tumor size
when applied to the AOM/DSS protocol (Fig. 1). Colorectal
tumors developed from Tg-tRXRα mice showed much more
profound macrophage infiltration and expressed high levels of
inflammatory cytokines (Fig. 3), demonstrating that the tumori-
genic effect of tRXRα is due to its modulation of the tumor
inflammatory microenvironment. This was supported by our
discovery that tRXRα expression in myeloid cells could promote
colorectal carcinogenesis (Fig. 4) and is in agreement with pre-
vious reports that RXRα plays an important role in regulating
macrophage functions and inflammatory disorders33,35. The role
of tRXRα in myeloid cells was further illustrated by our in vitro
experiments showing that ectopic expression of tRXRα but not of
RXRα in macrophages potentiated LPS induction of IκBα
degradation, NF-κB nuclear translocation, and expression of
several cytokines (Fig. 5). Thus the tumorigenic role of tRXRα
during CAC development is largely attributed to its activation of
the IKK-NF-κB pathway in macrophages. Our observations that
tRXRα is produced in colorectal tissues of ulcerative colitis
patients (Fig. 7a) and a majority of tumor tissues but not the
corresponding adjacent normal tissues from patients with color-
ectal tumor (Fig. 7b), suggest the clinical relevance of tRXRα
expression in the development of CAC.
Recent studies have provided important insight into the
molecular mechanisms linking chronic inflammation to the
development of cancers. Of particular important mechanism is
the activation of STAT3 by IL-661,62. However, the regulation of
the IL-6-STAT3 pathway during the development of CAC is still
obscure, which has hindered the development of effective
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strategies targeting the pathway. Our present data demonstrated
that tRXRα is an important modulator of the IL-6-STAT3 cascade
during colorectal tumorigenesis. Enhanced STAT3 phosphoryla-
tion was observed in Tg-tRXRα mice before (Fig. 2a) or after
treatment with AOM/DSS (Fig. 2a) or DSS alone (Fig. 2b).
Induction of STAT3 phosphorylation by tRXRα was fast, occur-
ring in 1 day after DSS treatment (Fig. 2f), suggesting a pivotal
role of tRXRα in the activation of STAT3. TNFα, another cyto-
kine known to activate the NF-κB pathway, whose activation
contributes to tumor development, was also upregulated in
tRXRα mice (Fig. 3). TNFα activation of the NF-κB signaling
induces the expression of inflammatory mediators and growth
factors. We previously reported that tRXRα could promote TNFα
activation of the PI3K/AKT signaling pathway, another important
pathway critical for cancer cell proliferation and survival25. AKT
activation was indeed enhanced in tRXRα transgenic mice chal-
lenged with AOM/DSS (Fig. 2a) or DSS (Fig. 2b). Taken together,
these results identified tRXRα as an important factor that med-
iates the causal link between chronic inflammation and the
development of CAC.
While how RXRα binds to DNA and regulates target gene
transcription is well understood, the non-transcriptional actions
regulated by RXRα and the underlying mechanisms remain
poorly understood. Given the fact that transcription-independent
action of RXRα and other nuclear receptors often involves their
interaction with important signal transduction proteins critical
for the growth and death of cancer cells, understanding the
molecular mechanism by which nuclear receptors exert their non-
transcriptional action may offer new strategies to explore their
therapeutic potential. One of the unique properties of tRXRα is its
cytoplasmic localization under inflammatory conditions9. Our
investigation of the molecular mechanism by which tRXRα acti-
vates the inflammatory pathway in macrophages revealed a pre-
viously unrecognized non-transcriptional role of tRXRα through
its interaction with TRAF6. TRAF6 is overexpressed in a variety
of cancers including colon cancer66,67. TRAF6 overexpression in
NIH3T3 cells resulted in NF-κB activation, anchorage-
independent growth, and tumor formation, whereas TRAF6
depletion inhibited cancer cell proliferation and tumorigenesis69,
demonstrating its oncogenic activity. As TRAF6 plays a key role
in the assembly of protein complexes necessary for the activation
of the IKK-NF-κB pathway, TRAF6 overexpression would lead to
constitutive NF-κB activation. Indeed, we found that TRAF6
expression was enhanced in Tg-tRXRα mice in the absence or
presence of AOM/DSS treatment (Fig. 2a). Moreover, TRAF6
expression was increased when tRXRα was expressed in myeloid
cells (Fig. 4f). While how tRXRα induces TRAF6 expression in
myeloid cells is currently unknown, we showed that coexpression
of TRAF6 and tRXRα synergistically induced IκBα degradation
(Fig. 6a) and NF-κB activation (Fig. 6b). Such an effect was likely
due to their physical interaction (Fig. 6), which led to auto-
ubiquitination of TRAF6, an event known to activate the IKK/
NF-κB pathway64. Interestingly, TRAF6 interacted with tRXRα
but not with RXRα, demonstrating that tRXRα activation of the
IKK-NF-κB pathway is a tumor-specific event. Thus tRXRα
activation of the NF-κB pathway in macrophages through its
interaction with cytoplasmic TRAF6 represents an important
non-transcriptional mechanism by which tRXRα promotes tumor
growth.
Our discovery that tRXRα plays a pivotal role in modulating
the IL-6-STAT3 pathway offers an effective and selective
approach to treat inflammation-associated cancers. NSAIDs have
demonstrated promising preventive and therapeutic effects
against colorectal cancer. Sulindac, one of the most studied
NSAIDs, is effective against colorectal cancer in various clinical
studies53,54. Unfortunately, long-term sulindac treatment has
several drawbacks, such as gastrointestinal bleeding associated
with COX1 inhibition and increased cardiovascular risk resulting
from COX2 inhibition70. Our previous discovery that tRXRα
serves as an intracellular target of sulindac led to our identifica-
tion of K-80003, a sulindac analog with enhanced tRXRα binding
and diminished COX inhibition activities25. We showed here that
K-80003 is a potent inhibitor of tRXRα-mediated colorectal car-
cinogenesis by inhibiting tRXRα-mediated NF-κB-IL-6-STAT3
pathway (Fig. 7). The effect of K-80003 is likely due to its ability
to induce tRXRα tetramerization52 that may serve to inhibit
tRXRα interaction with TRAF6. It is noteworthy that K-80003
exhibits very desirable pharmacological profiles including much
reduced side effects in animals25, which could be attributed to its
effective and selective induction of tetramerization of tRXRα but
not of RXRα52. The selective effect of K-80003 is expected to lead
to specific blockade of tRXRα in tumor cells without compro-
mising the normal function of RXRα. The ability of K-80003 to
bind to distinct and alternate hydrophobic grooves on the surface
of tRXRα52 may also contribute to its efficacy and selectivity, as
tRXRα may employ its surface grooves to interact with non-
transcriptional signaling proteins such as TRAF6.
Together, our results revealed an oncogenic effect of tRXRα in
the development and growth of CAC through its activation of the
IL-6-STAT3 signaling pathway and uncovered a new tRXRα non-
transcriptional mechanism responsible for the activation. Our
data also identify K-80003 as a promising anti-CAC agent that
targets the tRXRα pathway.
Methods
Mice. LoxP-tRXRα and loxP-RXRα mice were constructed by using pronuclear
microinjection. The detail sequences are presented in Supplementary Fig. 1a and
the sequence of loxp-tRXRα are the same with loxp-RXRα except that 85 N-
terminal amino acids in RXRα were deleted in loxp-tRXRα. CMV-Cre mice (B6.C-
Tg(CMV-cre)1Cgn/J) (Cat.J006054) and LysM-cre mice (B6.129P2-Lyz2tm1(cre)
Ifo/NJU) (Cat.J004781) were kindly provided by Professor Jia-huai Han (Xiamen
University). All of the mice were approved by the Animal Care and Use Committee
of Xiamen University and maintained with 12-h light/12-h dark cycles at the
Laboratory Animal Center in Xiamen University.
Antibody and reagent. Anti-RXRα (D20) (Cat. sc-553,1:1000), anti-RXRα
(ΔN197) (Cat. sc-774,1:1000), anti-Myc (9E10) (Cat. Sc-40, 1:1000), anti-TRAF6
(H-274) (Cat. sc-7221, 1:1000), anti-AKT (Cat. sc-8312, 1:1000), anti-β-catenin (E-
5, 1:1000) (Cat. sc-7963), anti-PCNA (FC-261, 1:100 dilution for immunohis-
tochemistry) (Cat. sc7907), and anti-p65 (Cat. sc-109) antibodies were from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Anti-IκBα (Cat. ab32518, 1:1000),
anti-pSTAT3 (Y705) (Cat. ab76315, 1:100,000), anti-Ki-67 (Cat.ab15580, 1:200
dilution for immunohistochemistry), and anti-CD68 (Cat. ab31630, 1:400 dilution
for immunohistochemistry) antibodies were from Abcam (UK). Anti-Ubiquitin
(Cat. 3933S), anti-STAT3 (Cat. 9139S, 1:1000), anti-p-IκBα (Cat. 9246, 1:1000),
anti-K63-ubiquitin (D7A11) (Cat.#5621, 1:1000), anti-TRAF6 (D21G3) (Cat.
8028S, 1:1000), anti-pGSK3β (Ser9) (Cat.#9336, 1:1000), and anti-pAKT (S473)
(Cat. 9271S, 1:1000) antibodies were from Cell Signal Technology (Beverly, MA,
USA). Anti-GSK3β (total) (Cat.610202, 1:1000) was from BD biosciences (San
Diego, USA). Anti-β-actin (Cat. A5441, 1:50,000) and anti-FLAG (Cat. F1804,
1:1000) antibodies were from Sigma (St. Louis, MO, USA). DSS (Cat.
0216011080100g) (MW:36000-50000) was from MP Biomedicals. AOM (Cat.
A5486), LPS (Cat. L2630), RXRα siRNA (SASI_Hs01_00097639,
SASI_Hs01_00097640, SASI_Rn02_00260246), and nonspecific control siRNA
were from Sigma. TianScript RT Kit (Cat. KR104-02) was from TianGen Bio-
technology (Beijing, China). Mouse IL-6 (Cat. KE10007) and TNFα (Cat. KE10002)
enzyme-linked immunosorbent assay kits for IL-6 and TNFα were from Pro-
teintech (Wuhan, China).
Induction of colitis and CAC. Mice (8–12-week old, male) were injected intra-
peritoneally with a single dose of AOM (10 mg/kg; Sigma, #A5486). After 7 days,
2.5% DSS (MP Biomedicals, #0216011080100g) was given in the drinking water for
7 days, followed by 14 days of regular drinking water. The DSS treatment was
repeated for two additional cycles, and mice were sacrificed 120 days after the
AOM injection. In the K-80003 treatment model, K-80003 (dissolved in dimethyl
sulfoxide (DMSO) and diluted with 0.9% NaCl containing 5.0% (V/V) Tween-80,
20 mg/kg) were administered via oral gavage daily in last 2 weeks. Normal saline
with DMSO and 5.0% Tween-80 was employed as the vehicle control. For short-
term colitis and inflammation studies, mice (8–10-week old) were given 3% DSS
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for 5 days, followed by regular drinking water for 4 days and sacrificed at the
indicated time points. Body weights were recorded daily. Colons were removed
from mice, flushed with cold phosphate-buffered saline (PBS), opened long-
itudinally, fixed as “swiss-rolls” in 4% formalin solution (Sigma, #16005-1KG-R),
and paraffin embedded. Before fixing the colons, tumor size measurements were
performed using a vernier caliper in a blinded fashion.
Clinical tumor samples. Human colorectal cancerous and para-cancerous tissues
were obtained from Zhongshan Hospital, Xiamen University, and human color-
ectal tissues from normal and ulcerative colitis patients were obtained from Soo-
chow University hospital with patient informed consent and approval of the
Medical Ethical Committee of Zhongshan Hospital and Soochow University hos-
pital, respectively.
Histopathological analysis and immunohistochemistry. Paraffin-embedded
colon sections were stained with H&E. The extent of inflammation was mea-
sured and scored. Paraffin-embedded slides were deparaffinized. Antigen
unmasking was carried out by heating in microwave in 10 mM sodium citrate
buffer for 5 min and cooling for 2 min, with repeat of this process five times.
Slides were incubated with primary antibodies in PBS. Horseradish peroxidase
secondary anti-rat or anti-rabbit antibodies (BIOTnA, cat#TAHC03D) were
added and incubated at room temperature for 1 h. The sections were stained
with DAB substrate and counterstained with hematoxylin. 10–15 fields were
randomly selected from each section at high magnification, photographed, and
analyzed by two pathologists previously uninformed. Histological scores were
assigned by experimenters “blinded” to sample identity. Colonic epithelial
damage was assigned scores as follows: 0= normal; 1= hyperproliferation,
irregular crypts, and goblet cell loss; 2=mild-to-moderate crypt loss (10–50%);
3= severe crypt loss (50–90%); 4= complete crypt loss, surface epithelium
intact; 5= small-to-medium-sized ulcer (<10 crypt widths); 6= large ulcer (≥10
crypt widths).
Real-time polymerase chain reaction. Total RNAs were extracted by Trizol
(Invitrogen) and complemental DNA were synthesized using TIANScript RT Kit
(Tiangen). Real-time PCR was performed using SYBR Green Master Mix following
the manufacturer’s instructions (Roche) on ABI Stepone PCR instrument using
respective primers (Supplementary Table 1). Expression data were normalized to
GAPDH mRNA expression.
Cell culture and transfection. RAW264.7, CV-1 cells, THP-1, and HEK293T were
purchased from the American Type Culture Collection (Manassas, VA, USA).
CT26.WT and HCT-116 were purchased form Cell Bank in Chinese Academy of
Sciences in Shanghai. RAW264.7, CV-1 cells, and HEK293T cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal bovine serum (FBS);
THP-1 cells were maintained in RPMI 1640 containing 10% fetal bovine serum in a
humidified atmosphere containing 5% CO2 at 37 °C. They were regularly tested for
mycoplasma contamination using the MycoFluorTM Mycoplasma Detection Kit
(ThermoFisher Scientific) and always found to be negative. Transient transfection
of HEK293T cells were carried out with calcium phosphate method. RAW264.7
cells, THP-1 cells, and CV-1 cells were transfected with Lipofectamin 2000
(Invitrogen). RAW264.7 stable cells lines expressing GFP, GFP-RXRα, and GFP-
tRXRα were selected with 600 μg/ml G418 for 3–4 weeks.
Isolation and culture of BMDMs. Bone marrow cells were flushed from the
femurs and tibias and treated with red blood cell lysis buffer (BD Biosciences,
cat555899) to get rid of blood cell. Single-cell suspensions were obtained by forcing
through a 40-mm cell strainer and differentiated into macrophages in DMEM
supplemented with 10% FBS, 30% L929 CM, and 1% penicillin and streptomycin
for 6–7days. Primary BMDMs were cultured with DMEM supplemented with 10%
FBS for experiments.
Condition medium and colony-formation assay. BMDMs were cultured with
DMEM supplemented with 10% FBS for 72 h. THP-1 cells were cultured with
RPMI1640 without FBS for 48 h. These media were collected, centrifuged with
10,000 × g for 20 min and stored at −80 °C. For culturing tumor cells, CM were
warmed up at 4 °C and used to culture tumor cells. In the colony assay, media were
used to culture tumor cells for 2 weeks in 6-well plate and colonies were fixed with
methylalcohol and stained with Giemsa.
Cell invasion assay. Cell invasion assay was performed with an invasion chamber
(BD Biosciences, cat #354480) pretreated with medium 2 h for matrix membrane
hydration. Tumor cells (HCT116 or MDA-MB-231, 2.5 × 104 per well, 1% FBS)
were seeded in the upper chamber, and the inflammatory cells (THP-1 cell, 1 × 105
per well, 1% FBS) were loaded into the lower chamber. After 36 h of incubation at
37 °C in 5% CO2, noninvasive cells were removed from the upper surface of the
transwell membrane with a cotton swab, and the invaded cells on the lower
membrane surface were fixed with paraformaldehyde (PFA) and stained with
Gimasa. Randomly selected fields were photographed and the numbers of migrated
cells per field were counted. For invasion assay using primary BMDMs and murine
CT26 colon cancer cells, CM from BMDMs were placed in the lower chamber and
CT26 colon cell were seeded in the upper chamber.
Plasmid constructions. Expression constructs for TRAF6 was kindly provided by
Dr. Ashley Mansell (Monash Institute of Medical Research, Australia). TRAF6/
ΔTRAF and TRAF6/ΔRING were generated by PCR and inserted into pCMV-Myc
vector. Plasmids encoding RXRα, RXRα/1–135, RXRα/1-235, and RXRα/223-462
were constructed using pEGFP-C1 vector.
Immunoprecipitation and ubiquitination assay. Cells were lysed in a buffer
containing 2 mmol/l Tris-HCl (pH7.4), 10 mmol/l EDTA, 100 mmol/l NaCl, and
1% IGEPAL. Whole-cell lysates were subjected to immunoprecipitation with
antibodies against RXRα (D20), RXRα (ΔN197), TRAF6, or c-Myc in protein A/G
beads (Santa Cruz Biotechnology). For detection of TRAF6 ubiquitination, 10 mM
N-ethylmaleimide was included in the lysis buffer containing a protease inhibitor
“cocktail” (Roche).
Immunoblotting (IB). IB was performed as described previously21,25,52. Briefly,
cell or tissue lysates were electrophoresed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride
membranes. The membranes were blocked with 5% skimmed milk in TBST (50
mM Tris-HCl (pH 7.4), 150 mM NaCl, and 0.1% Tween20) for 1 h, then incubated
with primary antibodies and secondary antibodies and detected using enhanced
chemiluminescence. The original immunoblots from the main figures are shown in
Supplementary Figure 8.
Confocal microscopy. Cells seeded on glass slides were washed with PBS and
fixed in 4% PFA for 15 min. Fixed cells were permeabilized with PBS containing
0.1% Triton X-100 for 15 min and blocked with 1 mg/ml bovine serum albumin
in PBS for 30 min at room temperature. Primary antibodies were incubated for 3
h at room temperature or overnight at 4 °C and secondary antibodies were
incubated at room temperature for 1 h. DAPI was dyed for visualizing nuclei.
The images were taken under an LSM-510 confocal laser scanning microscope
system (Carl Zeiss).
Luciferease report assay. RAW264.7 and THP-1 cells were transfected with
plasmids combined with pNF-κB-Luc for NF-κB reporter. After transfection for 24
h (48 h for siRNA), cells were lysed by reporter lysis buffer. Firefly and Renilla
luciferase activities were analyzed with the Dual-Luciferase Reporter Assay system
(Promega). Transfection and expression efficiency were normalized to Renilla
luciferase activity
Statistical analysis. Data are presented as mean ± standard error of the mean
(SEM) or ±standard deviation (SD), and statistical significance are reported in the
figure legends. Statistics was analyzed using Student’s t test, chi-square test, or
analysis of variance (ANOVA) analysis (one-way ANOVA for comparisons
between groups, two-way ANOVA for comparisons the magnitude of changes
between different groups from different cell lines). P < 0.05 was considered sta-
tistically significant (*), P < 0.01 as highly significant (**), P < 0.001 as extremely
significant (***), and ns as not significant.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Supporting data of this study are available from the corresponding author on reasonable
request. The source underlying Figs. 2a, b, f, 4f, 5c, f, h, 6a, e–i, 7a, b, g and
Supplementary Figs. 1c, 4c, 4d, 5a, 5c, 6a, 6c–f, 7e, 7g, 7j are provided as a Supplementary
Data 1. A reporting summary for this article is available as a Supplementary Information
file.
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